Article from Cloud-based Medicine Studio | A national authoritative medical organization for rare diseases will be established, and the second list of rare diseases will be updated
(attachments: the first list and the national reimbursement drug list)
First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 2 Trial for the Treatment of Gaucher Disease in china
CANbridge Congratulates Apogenix on First Patient Dosed in Asunercept (CAN008) Phase 3 Trial for the Treatment of COVID-19
-CANbridge holds exclusive rights for the development of CAN008 for any indication in Greater China
-CAN008 currently in Phase 2 trial for the treatment of glioblastoma multiforme in China
CANbridge Consolidates Gene Therapy Portfolio
-Secures Exclusive Global Rights to Potentially Best-in-Class Spinal Muscular Atrophy Gene Therapy from UMass Chan Medical School
-Completes Technology Transfer of Two Gene Therapies for Lysomal Storage Diseases